 OSLO, Norway--BUSINESS WIRE--- ULTI--Ultimovacs ASA Ultimovacs, ticker ULTI, today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the Companys Tetanus-Epitope Targeting TET-platform. The platform allows for the production of multiple therapeutic cancer vaccines that can be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tum 